News

27 June 2017

Verona Pharma Receives Regulatory Approval to Commence Phase 2b Clinical Trial of RPL554 for COPD Maintenance Treatment in Five Countries across Europe

LONDON, June 27, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today regulatory appr…

Read more

22 June 2017

Verona Pharma Appoints Dr. Desiree Luthman as Vice President of Regulatory Affairs

LONDON, June 22, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, today announces the appointment…

Read more

6 June 2017

Holding(s) in Company

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i)

Read more

6 June 2017

Holding(s) in Company

 

Read more

5 June 2017

Verona Pharma Initiates U.S. Clinical Pharmacokinetic Study for RPL554 Following Acceptance of IND Application by FDA

LONDON, June 05, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with signifi…

Read more

30 May 2017

Holding(s) in Company

 

Read more

30 May 2017

Holding(s) in Company

 

Read more

25 May 2017

Holding(s) in Company

 

Read more

23 May 2017

Verona Pharma to Present at Jefferies 2017 Global Healthcare Conference

LONDON, May 23, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases with signifi…

Read more

23 May 2017

Holding(s) in Company

Read more

Realising multiple value creation opportunities with a unique respiratory product RPL554

AGM presentation

27 June 2016

The Lancet Respiratory Medicine

Peer-reviewed paper in the Lancet's highly-respected medication journal

Targeting unmet needs

210m people worldwide suffer from COPD and 37 years is the median life expectancy of CF patients

Close

Verona Pharma plc
3 More London Riverside, London SE1 2RE
T: +44 (0)203 283 4200

Linkedin     Email Us